Neumora Therapeutics Inc
NMRA1.685USD
+0.125+8.04%
交易中 （美東）報價延遲15分鐘
272.63M總市值
虧損本益比TTM
關於 Neumora Therapeutics Inc 公司
Neumora Therapeutics Inc. 是一家臨牀階段的生物製藥公司。該公司的治療產品線包括七個臨牀和臨牀前神經科學項目，旨在爲廣泛的未得到充分治療的神經精神疾病和神經退行性疾病提供新的治療機制。其先進的候選產品 navacaprant (NMRA-140) 是一種新型的每日一次口服 kappa 阿片受體 (KOR) 拮抗劑，正在開發用於治療抑鬱症 (MDD)。其其他候選藥物包括 NMRA-266、NMRA-511 和 NMRA-NMDA。NMRA-266 是 M4 毒蕈鹼受體 (M4R) 的正變構調節劑程序，用於治療精神分裂症。NMRA-266 旨在選擇性地針對毒蕈鹼受體家族的 M4 受體亞型。 NMRA-511 是一種在研的加壓素 1a 受體 (V1aR) 拮抗劑。NMRA-NMDA 是一種 NMDA 正向變構調節劑方案，該公司正在開發該方案用於治療精神分裂症。
公司簡介
公司代碼NMRA
公司名稱Neumora Therapeutics Inc
上市日期Sep 15, 2023
CEOMr. Paul L. Berns
員工數量110
證券類型Ordinary Share
年結日Sep 15
公司地址490 Arsenal Way
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02472
電話18577600900
網址https://neumoratx.com/
公司代碼NMRA
上市日期Sep 15, 2023
CEOMr. Paul L. Berns
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
27.62K
--
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Jason G. Duncan
Mr. Jason G. Duncan
Chief Legal and Administrative Officer
Chief Legal and Administrative Officer
--
--
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.68M
+3.27%
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
130.51K
+46.75%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
27.62K
--
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
22.47K
-8.09%
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Amgen Inc
21.87%
ARCH Venture Partners
19.74%
Berns (Paul L)
4.75%
SB Global Advisers Ltd
4.04%
BlackRock Institutional Trust Company, N.A.
3.49%
Other
46.11%
持股股東
持股股東
佔比
Amgen Inc
21.87%
ARCH Venture Partners
19.74%
Berns (Paul L)
4.75%
SB Global Advisers Ltd
4.04%
BlackRock Institutional Trust Company, N.A.
3.49%
Other
46.11%
股東類型
持股股東
佔比
Investment Advisor
24.47%
Corporation
21.87%
Venture Capital
21.03%
Investment Advisor/Hedge Fund
6.00%
Individual Investor
5.65%
Hedge Fund
3.95%
Endowment Fund
2.05%
Research Firm
1.66%
Bank and Trust
1.40%
Other
11.93%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
286
142.72M
88.23%
-24.78M
2025Q1
283
144.00M
90.43%
+12.16M
2024Q4
249
161.18M
99.54%
+45.20M
2024Q3
201
148.65M
93.66%
+40.67M
2024Q2
179
142.61M
90.03%
+47.65M
2024Q1
154
133.89M
85.01%
+50.39M
2023Q4
108
122.49M
78.90%
+50.97M
2023Q3
54
110.63M
71.42%
+110.63M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Amgen Inc
35.37M
21.87%
--
--
Apr 10, 2025
ARCH Venture Partners
31.93M
19.74%
--
--
Nov 12, 2024
Berns (Paul L)
7.68M
4.75%
+242.77K
+3.27%
Apr 10, 2025
SB Global Advisers Ltd
6.54M
4.04%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.65M
3.49%
-433.37K
-7.13%
Mar 31, 2025
The Vanguard Group, Inc.
5.33M
3.29%
+766.67K
+16.82%
Mar 31, 2025
Invus Public Equities Advisors, LLC
4.36M
2.69%
-37.82K
-0.86%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.50M
2.16%
-4.23M
-54.72%
Mar 31, 2025
Wellcome Trust
3.31M
2.05%
--
--
Mar 31, 2025
ICONIQ Capital, LLC
2.56M
1.58%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0%
ALPS Medical Breakthroughs ETF
0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0%
iShares Russell 3000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0%
ALPS Medical Breakthroughs ETF
佔比0%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
